Axonics, Medtronic
Jury rules for Axonics in Medtronic’s long-running neuromodulation patent lawsuit
A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run afoul of three patents held by the company’s main rival, Medt | The case is one of several intellectual property disputes between the medtech giant and Axonics—which is currently waiting to become a subsidiary of Boston Scientific.
While it may not be enough for some shareholders, we think it is good to see the Medtronic plc ( NYSE:MDT ) share ...
Medtronic PLC closed $2.15 below its 52-week high ($91.49), which the company reached on September 4th.
Analyst Travis Steed of Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report), retaining the price ...
Medtronic, a global developer and manufacturer of medical devices for chronic diseases, is now a $111 billion (by market cap) ...
Medtronic PLC closed $1.38 below its 52-week high ($91.49), which the company achieved on September 4th.
"Medtronic’s Aurora EV-ICD to challenge Boston Scientific’s S-ICD market leadership" was originally created and published by ...
Medtronic may be an underrated beneficiary of declining interest rates. That's because as rates come down, it becomes less ...
In April, Medtronic obtained FDA approval for another new product, Inceptiv, a spinal cord stimulator for treating chronic pain. The device can automatically adjust the therapy — a unique feature — to ...
Medtronic (NYSE: MDT) has named Jorie Soskin as its new VP and GM of its TAVR and Congenital Heart businesses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback